Answers are grounded in this paper and cite their sources.
This letter was originally published in NDT volume 19, issue 7, but without the Reply. The publisher would like to apologise for this error and would now like to publish the paper again to include the Reply. Sir, We read with interest the original report made by Miguel-Angel Guillen-Anaya and Michel Jadoul [1] of a drug interaction between sevelamer and cyclosporin (CsA) occurring in a liver transplant patient treated also by chronic haemodialysis. After sevelamer was started, the CsA trough levels reached values as low as 35 ng/ml and they dropped again after rechallenge. As potential explanation, the authors suggest that CsA absorption, which is bile-dependent [2], could be hampered by the fact that sevelamer binds bile acids in the gastrointestinal (GI) tract. Interestingly, in the clinical study performed by Jensen et al. [3], the bile-acid sequestrant cholestyramine, 4 g given at noon, did not interfere with CsA absorption. We would like to mention that sevelamer is a poly(allylaminehydrochloride) polymer that may bind not only phosphate and bile acids, as the authors point out, but also cholesterol, vitamins D, E and K and folic acid [4]. A direct binding of a lipophilic substance such as CsA – and by extension also tacrolimus – appears, therefore, as an additional and more likely explanation. This observation points to the distinction to be made between the two types of phosphate binding in the GI tract: a specific one achieved by aluminium hydroxide and calcium salts and a non-specific binding attained by polymers such as sevelamer. This absence of specificity might be of less importance for vitamins or folic acid absorption, but may put the patient at risk when lipophilic agents, such as immunosuppressive and/or other drugs (lipophilic statins?), are prescribed. Under those circumstances, it appears that sevelamer should be used with caution, i.e. at least at a time distant of potentially interfering drugs and only when specific (and less expensive) phosphate binders are contraindicated. Conflict of interest statement. None declared. Sir, We thank Jean-Pierre Wauters and colleagues for their helpful comments. The lower level of cyclosporin A (CsA) under sevelamer may indeed be due to a direct binding of CsA by sevelamer, rather than to an indirect impact of sevelamer on bile acids. Thus, the recommendation of a delay between the intake of sevelamer and that of drugs such as CsA is fully warranted. We disagree, however, on the claim that calcium-based binding is fully specific for phosphate. Indeed, the co-administration of either calcium acetate or sevelamer with ciprofloxacin recently has been shown to reduce the oral bioavailability of the latter drug by some 50% [1]. Conflict of interest statement. None declared.
No takes yet. Share an insight, caveat, or question.
Wauters et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: